Drug guidance
Deucravacitinib for moderate-to-severe chronic plaque psoriasis
Condition
Blood and Immune System
Skin
17 February 2025
Published on 17 Feb 2025
Last Updated on 17 Feb 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended deucravacitinib for inclusion on the MOH List of Subsidised Drugs for treating moderate-to-severe chronic plaque psoriasis. The decision was based on the unfavourable clinical and cost effectiveness of deucravacitinib compared with adalimumab, and the unacceptable price-volume agreement proposed by the company.
Deucravacitinib for moderate-to-severe chronic plaque psoriasis (17 Feb 2025) [PDF, 246 KB]